13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AtTEND

    Acronym: 

    AtTEND

    ACTRN/NCT /ethics: 

    ACTRN12619000900112

    Scientific title: 

    Atezolizumab Trial in Endometrial cancer. | AtTEnd

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III Tumour Stream Endometrial Cancer
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Female Anticipated Start Date 2019-10-01
    Molecular Target Anticipated End Date 2022-07-31
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Endometrial Cancer
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2019-10-01
    Anticipated End Date 2022-07-31

    Trial Summary

    This study is testing a new cancer treatment, atezolizumab, given in combination with standard chemotherapy (paclitaxel and carboplatin) for endometrial cancer

    Lay Summary

    Atezolizumab Trial in Endometrial cancer. | AtTEnd

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Dr Sid Selva Not Yet Recruiting